Determination of illicit drug cutoff values in a pain patient population

Clinica Chimica Acta

Volumn 412, Issue 17-18, 2011, Pages 1589-1593

  West, Robert ^a   Pesce, Amadeo J ^a   Crews, Bridgit ^a   Mikel, Charles ^a   Rosenthal, Murray ^a   Almazan, Perla ^a   Latyshev, Sergey ^a   West, Cameron ^a  

^a Millennium Research Institute   (United States)

Author keywords

Cocaine; Cutoffs; LC MS MS; Marijuana; Methamphetamine; Urine drug testing

Indexed keywords

BENZOYLECGONINE; CANNABIS; CREATININE; ILLICIT DRUG; METHAMPHETAMINE;

ANALYTIC METHOD; ARTICLE; CHRONIC PAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABUSE; DRUG URINE LEVEL; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; REFERENCE VALUE; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; COHORT STUDIES; HUMANS; PAIN; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

CANNABIS SATIVA;

EID: 80955178303     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.05.004     Document Type: Article

References (22)

1. Manchikanti L., Damron K., McManus C.D., Barnhill R.C. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: a prospective, observational study. Pain Physician 2004, 7(4):431-437.
2. Manchikanti L., Manchukonda R., Pampati V., Damron K., Brandon D., Cash K.A., et al. Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?. Pain Physician 2006, 9(2):123-129.
3. Manchikanti L., Cash K.A., Damron K.S., Manchukonda R., Pampati V., McManus C.D. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician 2006, 9(3):215-226.
4. Manchikanti L., Manchukonda R., Pampati V., Damron K.S. Evaluation of abuse of prescription and illicit drugs in chronic pain patients receiving short-acting (hydrocodone) or long-acting (methadone) opioids. Pain Physician 2005, 8(3):257-261.
5. Cone E.J., Caplan Y.H., Black D.L., Robert T., Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol 2008, 32(8):530-543.
6. Pesce A., West C., Rosenthal M., West R., Crews B., Mikel C., et al. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician 2010, 13(3):283-287.
7. Reisfield G.M., Salazar E., Bertholf R.L. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007, 37(4):301-314.
8. Reisfield G.M., Wasan A.D., Jamison R.N. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med 2009, 10(8):1434-1441.
9. Mandatory Guidelines for Federal Workplace Drug Testing Programs. Substance Abuse and Mental Health Services Administration, HHS. Federal Register Vol 73, No.228 Tuesday, November 25, 2008.
10. Wingert W.E. Lowering cutoffs for initial and confirmation testing for cocaine and marijuana: large-scale study of effects on the rates of drug-positive results. Clin Chem 1997, 43(1):100-103.
11. Pesce A., Rosenthal M., West R., West C., Crews B., Mikel C., et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Physician 2010, 13(3):273-281.
12. Hattab E.M., Goldberger B.A., Johannsen L.M., Kindland P.W., Ticino F., Chronister C.W., et al. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: use for detecting maternal and neonatal drug exposures. Ann Clin Lab Sci 2000, 31(1):85-91.
13. Fraser A.D., Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003, 25(6):723-727.
14. House of Delegates of the Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain 2004, Accessed May 25, 2010 from. http://www.fsmb.org/pdf/2004_grpol_controlled_substances.pdf.
15. Chou R., Fanciullo G.J., Fine P.G., Adler J.A., Ballantyne J.C., Davies P., et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10(2):113-130.
16. West R., Pesce A., West C., Crews B., Mikel C., Almazan P., et al. Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS/MS in pain management population. Pain Physician 2010, 13(1):71-78.
17. Pesce A., West C., West R., Crews B., Mikel C., Almazan P., et al. Reference intervals: A novel approach to detect drug abuse in a pain patient population. J Opioid Manag 2010, 6(5):341-350.
18. Wu A.H.B. Urine adulteration before testing for drugs of abuse. The clinical toxicology laboratory: contemporary practice of poisoning evaluation 2001, 157-171. American Association for Clinical Chemistry, Inc., Washington, DC. L.C. Shaw, T.C. Kwong, T.G. Rosano, P.J. Orsolak, B.A. Wolf, B. Magnani (Eds.).
19. Niedbala S., Kardos K., Salamone S., Fritch D., Bronsgeest M., Cone E.J. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol 2004, 28(7):546-552.
20. ElSohly M.A., Jones A.B. Drug testing in the workplace: could a positive test for one of the mandated drugs be for reasons other than illicit use of the drug?. J Anal Toxicol 1995, 19:450-458.
21. Kavnagh K.T., Maijub A.G., Brown J.R. Passive exposure to cocaine in medical personnel and its effect on urine drug screening tests. Otolaryngol Head Neck Surg 1992, 107:363-366.
22. Mikel C., Almazan P., West R., Pesce A., West C., Latyshev S., et al. LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit 2009, 31:746-748.